je.st
news
Tag: insulin
Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
2014-06-14 19:01:32| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION Real-world study presented at the American Diabetes Association 74th Scientific Sessions Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more
New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo
2014-06-14 19:01:06| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: English read more
Mannkind's inhaled insulin clears big hurdle
2014-04-03 06:15:09| Biotech - Topix.net
Danbury-based MannKind's hopes for Afrezza, an inhaled diabetes drug, took a major step forward this week when an advisory panel recommended the Food and Drug Administration approve the treatment.
Tags: big
insulin
clears
hurdle
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
2014-02-10 14:43:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Language: English Contact: Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
enter
agreement
develop
Eli Lilly And Company And Boehringer Ingelheim Announce New Drug Application Filing In The U.S. For New Insulin Glargine Product
2013-12-23 00:57:30| drugdiscoveryonline News Articles
Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin